Reducing the cost and time of developing antibodies

Sheun Oshinbolu
Industrial Fellow 2016

Sheun Oshinbolu
GlaxoSmithKline and University College London

Antibodies can be designed by bio-pharmaceutical companies to target patient diseases such as cancer. However, the procedures involved are extremely complex and costly.

The design process begins with thousands of potential antibodies, which have to meet certain quality criteria. One of these standards, aggregation, can only be tested following time and cost consuming purification. Aggregation refers to the “clumping” of antibodies which can be the make-or-break of medicinal development and is one of the main barriers to rapid drug manufacture.

Sheun is looking at ways of measuring aggregation using Fluorescence Resonance Energy Transfer (FRET) techniques. This will provide key quality information on the potential antibodies and allow companies to make better and earlier decisions, thus reducing time and costs spent on the development and ultimately selecting superior quality antibodies.

"Antibodies can be designed to target patient diseases"

Sheun studied MEng in Biochemical Engineering at University College London (UCL), which included a one-year study abroad at the Rensselsaer Polytechnic Institute in New York, USA. She graduated with first-class honours in 2014 and went on to commence an EngD in Biochemical Engineering and Bioprocess Engineering at UCL in collaboration with GlaxoSmithKline.

The Engineer
Lab News
The Manufacturer